Prostate Cancer International is
for 2011 by Great NonProfits
Acccording to an article on the Medscape web site today, the convicted “Lockerbie bomber,” Abdelbaset al Megrahi, finally died on Sunday, 2 years and 9 months after his release from a Scottish prison on compassionate grounds because he was close to dying of terminal prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, al Megrahi, survival | 3 Comments »
According to an article in today’s Annals of Internal Medicine, the U.S. Preventive Services Task Force or USPSTF has confirmed its prior draft recommendation against all “routine” use of PSA testing for risk of prostate cancer, stating that ”This recommendation applies to men in the general U.S. population, regardless of age.” … READ MORE …
Filed under: Diagnosis, Risk | Tagged: PSA, risk, screening, USPSTF | 3 Comments »
A Letter to the Editor just published in the journal Nature Genetics has suggested that that so-called SPOP mutations may be responsible for between 6 and 15 percent of the prostate cancers diagnosed in the USA each year. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: gene, mutation, SPOP, subtype, targeted | Leave a Comment »
There is a “nice” post today about surviving chemotherapy on Dr. Craig Hildreth’s cancer blog on the CancerNetwork.com web site. (“Nice” is in inverted commas because not much about chemotherapy is actually nice … but if you, your oncologist, and the oncologist’s office team think about chemo in the way Dr. Hildreth describes, it sure as heck can help!)
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: chemotherapy | Leave a Comment »
According to an article by Andrew Pollack in today’s issue of the New York Times, a company called Osisris Therapeutics has achieved the first-ever approval to market a therapy based on stem cells — in Canada, for children with a condition known as graft versus host disease or GvHD, which is a well-recognized complication of bone marrow transplantation. … READ MORE …
Filed under: Uncategorized | Tagged: stem cells | Leave a Comment »
A media release issued by Henry Ford Health System earlier today has a distinctly misleading headline that reads as follows: “Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery.” You need to read the content of the media release with care to understand that this headline is by no means an accurate summation of the results of the study referred. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: hospital, outcome, surgery, surgical, volume | 2 Comments »
According to information on the web site of the National Institute for Clinical Excellence (NICE), revised draft guidance has been issued by NICE regarding the routine use of abiraterone acetate. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, access, NICE, UK | 1 Comment »
According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical specimens in a small percentage of men diagnosed with high-risk disease. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: abiraterone, dutasteride, enzalutamide, leuprolide, MDV3100, neoadjuvant, pre-surgical | 6 Comments »
According to recent articles in the media, the National Institute for Clinical Excellence (NICE) will shortly issue a recommendation that abiraterone is covered for routine use in the UK among men with chemotherapy-refractory, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, NICE, UK | 2 Comments »
On Wednesday this week, you can join an hour-long webcast at which Dr. Carolyn Best and a colleague from the Department of Defense Prostate Cancer Research Program (DoD PCRP) will explain what is involved and how to apply. Sign yourself up right NOW! … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Leave a Comment »
According to a media release from the Mayo Clinic earlier today, “Alterations to the ‘on-off’ switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches.” … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: aggressiveness, DNA, expression, gene, methylation, test | 2 Comments »
According to an article in the Boston Globe this morning, we are (supposedly and finally) going to get the study needed to try to demonstrate whether there is a real clinical benefit to proton beam radiation therapy as compared to modern, intensity-modulated radiation therapy in men with localized prostate cancer! … READ MORE …
Filed under: Management, Treatment | Tagged: IMRT, PBRT, photon, proton, radiation therapy | 2 Comments »
Here is a link to a recent 20-minute video-discussion on the Medscape web site between an number of European experts on evolutions in the management of castration-resistant (and earlier forms of) prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: advanced, castration-resistant, mCRPC, review, video | Leave a Comment »
According to a media release issued today by the National Institute for Clinical Excellence (NICE) in the UK, the institute’s advisory board will not recommend “routine” use of cabazitaxel for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, NICE, UK | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site